Drug Profile
Olverembatinib - Ascentage Pharma
Alternative Names: APG 1351; BCR-ABL TKI; D 824; GZD 824; HQP 1351; IBI-348Latest Information Update: 08 Mar 2024
Price :
$50
*
At a glance
- Originator Guangzhou Institutes of Biomedicine and Health
- Developer Ascentage Pharma; Innovent Biologics
- Class Antineoplastics; Benzamides; Fluorinated hydrocarbons; Piperazines; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Cytokine inhibitors; Fms-like tyrosine kinase 3 inhibitors; Proto oncogene protein c-kit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic myeloid leukaemia
- Phase III Precursor cell lymphoblastic leukaemia-lymphoma
- Phase I/II Gastrointestinal stromal tumours; Solid tumours
- Preclinical Acute myeloid leukaemia; COVID 2019 infections; Renal cell carcinoma
Most Recent Events
- 05 Mar 2024 Pharmacodynamics data from a preclinical study in Cancer released by Ascentage Pharma
- 28 Dec 2023 No recent reports of development identified for phase-I development in Chronic-myeloid-leukaemia(Combination therapy, Second-line therapy or greater) in USA (PO)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Chronic-myeloid-leukaemia(Monotherapy, Second-line therapy or greater) in USA (PO)